A Strong Start For Amvuttra, But Alnylam Bides Time On Heart Results And US Price Control Plans

Company Will Await Full Readout In 2024

 
• By Andrew McConaghie
  
Alnylam building
Alnylam's HELIOS-B study is expected to read out in early 2024, allowing it to take on Pfizer's Vyndaqel and Vyndamax. • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip